GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Greenbrook TMS Inc (TSX:GTMS) » Definitions » Debt-to-EBITDA

Greenbrook TMS (TSX:GTMS) Debt-to-EBITDA : -2.28 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Greenbrook TMS Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Greenbrook TMS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$14.65 Mil. Greenbrook TMS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$160.60 Mil. Greenbrook TMS's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-76.72 Mil. Greenbrook TMS's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -2.28.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Greenbrook TMS's Debt-to-EBITDA or its related term are showing as below:

TSX:GTMS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.43   Med: -1.66   Max: -0.08
Current: -4.43

During the past 9 years, the highest Debt-to-EBITDA Ratio of Greenbrook TMS was -0.08. The lowest was -4.43. And the median was -1.66.

TSX:GTMS's Debt-to-EBITDA is ranked worse than
100% of 422 companies
in the Healthcare Providers & Services industry
Industry Median: 2.58 vs TSX:GTMS: -4.43

Greenbrook TMS Debt-to-EBITDA Historical Data

The historical data trend for Greenbrook TMS's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenbrook TMS Debt-to-EBITDA Chart

Greenbrook TMS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -2.60 -2.06 -3.26 -1.40 -3.79

Greenbrook TMS Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 - - - -2.28

Competitive Comparison of Greenbrook TMS's Debt-to-EBITDA

For the Medical Care Facilities subindustry, Greenbrook TMS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenbrook TMS's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Greenbrook TMS's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Greenbrook TMS's Debt-to-EBITDA falls into.



Greenbrook TMS Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Greenbrook TMS's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(14.653 + 160.604) / -46.201
=-3.79

Greenbrook TMS's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(14.653 + 160.604) / -76.724
=-2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Greenbrook TMS  (TSX:GTMS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Greenbrook TMS Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Greenbrook TMS's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenbrook TMS (TSX:GTMS) Business Description

Traded in Other Exchanges
Address
890 Yonge Street, 7th Floor, Toronto, ON, CAN, M4W 3P4
Greenbrook TMS Inc is a provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided over 11,00,000 TMS treatments to over 31,000 patients struggling with depression.

Greenbrook TMS (TSX:GTMS) Headlines

No Headlines